Precision Medicine in Oncology® | Specialty

Upfront Afatinib Bests Gefitinib in Phase II Lung Cancer Study

December 22nd 2015

Frontline treatment with afatinib reduced the risk of progression or death by 27% compared with gefitinib for patients with EGFR-mutant non–small cell lung cancer.

It's Time for True Advances in Comparative Effectiveness Research

December 21st 2015

It is simply unrealistic and highly counterproductive to the future of cancer care to believe that the only acceptable approach to determining the absolute or relative clinical utility of a specific drug, regimen, device, or procedure, is through the conduct of a so-called evidence-based randomized trial.

Gargi Basu on Alterations in the Cell Cycle Checkpoint Pathway in Breast Cancer

December 17th 2015

Gargi D. Basu, PhD, senior director of Clinical Curation, Ashion Analytics, discusses a study that examined alterations in the cell cycle checkpoint pathway in patients with breast cancer.

Dr. Omid Hamid on Vemurafenib and Atezolizumab in Melanoma

December 14th 2015

Omid Hamid, MD, Chief, Translational Research and Immunotherapy, Director, Melanoma Therapeutics, The Angeles Clinic, discusses a recent trial investigating the combination of vemurafenib and atezolizumab in melanoma in patients with previously untreated BRAF-positive unresectable or metastatic melanoma.

Dr. Gregory Riely on Using Next-Generation Sequencing to Identify Lung Cancer Mutations

December 3rd 2015

Gregory Riely, MD Medical Oncologist, Vice Chair, Clinical Trials Office, Department of Medicine, Memorial Sloan Kettering, discusses the benefits and challenges of using next-generation sequencing to identify mutations in lung cancer.

Outdated Metrics in the Age of Precision

December 2nd 2015

With the rapid pace of change in precision medicine, insurance companies and federal policymakers are going to have to adjust for far more variance in the ways patients are treated, even though insurance plans and federal policy by nature require a measure of standardization.

Dr. Gilbert on Precision Medicine in Glioblastoma

November 23rd 2015

Mark R. Gilbert, MD, senior investigator, chief, Neuro-Oncology Branch, National Cancer Institute, Center for Cancer Research, discusses the use of precision medicine in treating patients with glioblastoma.

Optimizing Precision Medicine Approaches in Glioblastoma

November 22nd 2015

The deployment of precision medicine to develop safe and effective therapies to treat malignant brain tumors is an effort that poses both opportunities and challenges.

Yale Cancer Center Merges Cutting Edge Research with Personalized Medicine

November 21st 2015

Dr. Jason Luke on Utilizing the Tumor Microenvironment as a Biomarker for Immunotherapy Response

November 20th 2015

Jason Luke, MD, Assistant Professor of Medicine, the University of Chicago Medicine Comprehensive Cancer Center, discusses how inflammation in the tumor microenvironment can serve as a biomarker in melanoma.

FDA Requests Additional Data for Rociletinib in EGFR T790M-Mutant NSCLC

November 16th 2015

The FDA has requested additional clinical trial data to support a new drug application for rociletinib as a potential therapy for pretreated patients with EGFR T790M mutation-positive NSCLC.

FDA Approves Osimertinib for EGFR T790M-Positive NSCLC

November 13th 2015

The FDA has granted an accelerated approval to osimertinib for patients with advanced EGFR T790M mutation positive non–small cell lung cancer following prior therapy on a prior EGFR TKI.

Dr. Oxnard on Delaying Second-Line Treatment in EGFR-Mutant Lung Cancer

November 9th 2015

Geoffrey R. Oxnard, MD, Assistant Professor of Medicine, Harvard Medical School, Dana Farber Cancer Institute, discusses how to define resistance to EGFR-inhibitors in lung cancer.

Targeting Rare Mutations in NSCLC the Way of the Future

November 7th 2015

Treatment of patients with non–small cell lung cancer should be based on the identification of rare molecular targets such as BRAF, RET, ROS1, and MET versus clinical characteristics.

Personalizing Cancer Drugs: The Next Front in Diagnostics

October 28th 2015

Less than a decade after the FDA set the ground rules for developing assays that pair molecular targets with new drugs, experts say there have been strides in personalizing anticancer therapies but that many hurdles remain before next-generation sequencing and other precision medicine advances are incorporated into the diagnostic paradigm.

Pazopanib's Activity in Thyroid Cancer Not Predicted by Thyroglobulin

October 22nd 2015

Pazopanib demonstrated significant clinical activity for patients with RAI-refractory differentiated thyroid cancer; however, a predictive biomarker for the therapy could not be uncovered.

Future Directions in Soft Tissue Sarcoma

October 21st 2015

Phase III Data on Eribulin in Advanced STS

October 21st 2015

Early Data With Olaratumab in Soft Tissue Sarcoma

October 21st 2015

Patient Selection in Soft Tissue Sarcoma

October 21st 2015